- Home
- UAL vs INSM Comparison
UAL vs INSM Comparison
Compare UAL & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UAL | INSM |
|---|---|---|
| Founded | 1934 | 1988 |
| Country | United States | United States |
| Employees | 87000 | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.8B | 30.1B |
| IPO Year | 1995 | 2000 |
Fundamental Metrics
Financial Performance| Metric | UAL | INSM |
|---|---|---|
| Price | $98.79 | $143.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 24 |
| Target Price | $130.59 | ★ $201.17 |
| AVG Volume (30 Days) | ★ 7.8M | 2.4M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.94 | N/A |
| EPS | ★ 10.20 | N/A |
| Revenue | ★ $37,736,000,000.00 | N/A |
| Revenue This Year | $10.86 | $182.31 |
| Revenue Next Year | $5.55 | $65.19 |
| P/E Ratio | $9.98 | ★ N/A |
| Revenue Growth | ★ 3.23 | N/A |
| 52 Week Low | $65.26 | $63.81 |
| 52 Week High | $119.21 | $212.75 |
Technical Indicators
Market Signals| Indicator | UAL | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 54.42 | 41.41 |
| Support Level | $86.54 | $142.99 |
| Resistance Level | $103.43 | $149.08 |
| Average True Range (ATR) | 4.12 | 5.62 |
| MACD | 1.21 | -1.75 |
| Stochastic Oscillator | 64.42 | 11.10 |
Price Performance
Historical ComparisonAbout UAL United Airlines Holdings Inc.
Chicago-based United Airlines is a major US network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel, especially across the Pacific, than its large US peers.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.